These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 16086927)

  • 1. Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study.
    Solomon SD; Skali H; Bourgoun M; Fang J; Ghali JK; Martelet M; Wojciechowski D; Ansmite B; Skards J; Laks T; Henry D; Packer M; Pfeffer MA;
    Am Heart J; 2005 Aug; 150(2):257-62. PubMed ID: 16086927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).
    Packer M; Califf RM; Konstam MA; Krum H; McMurray JJ; Rouleau JL; Swedberg K
    Circulation; 2002 Aug; 106(8):920-6. PubMed ID: 12186794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial.
    Rouleau JL; Pfeffer MA; Stewart DJ; Isaac D; Sestier F; Kerut EK; Porter CB; Proulx G; Qian C; Block AJ
    Lancet; 2000 Aug; 356(9230):615-20. PubMed ID: 10968433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of omapatrilat on cardiac nerve sprouting and structural remodeling in experimental congestive heart failure.
    Cha YM; Redfield MM; Shah S; Shen WK; Fishbein MC; Chen PS
    Heart Rhythm; 2005 Sep; 2(9):984-90. PubMed ID: 16171755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasopeptidase inhibition has beneficial cardiac effects in spontaneously diabetic Goto-Kakizaki rats.
    Grönholm T; Cheng ZJ; Palojoki E; Eriksson A; Bäcklund T; Vuolteenaho O; Finckenberg P; Laine M; Mervaala E; Tikkanen I
    Eur J Pharmacol; 2005 Sep; 519(3):267-76. PubMed ID: 16137672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the vasopeptidase inhibitor omapatrilat on peri- and postmyocardial infarction in Zucker lean rats.
    Lapointe N; Parker TG; Tsoporis JN; Nguyen QT; Marcotte F; Adam A; Lou I; Rouleau JL
    Can J Cardiol; 2005 Mar; 21(3):291-7. PubMed ID: 15776120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual inhibition of ACE and NEP provides greater cardioprotection in mice with heart failure.
    Xu J; Carretero OA; Liu YH; Yang F; Shesely EG; Oja-Tebbe N; Yang XP
    J Card Fail; 2004 Feb; 10(1):83-9. PubMed ID: 14966779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vasopeptidase inhibition in a canine model of exercise-induced left ventricular dysfunction.
    Holzgrefe HH; Arthur SR; Powell JR
    Clin Exp Pharmacol Physiol; 2002 Aug; 29(8):696-703. PubMed ID: 12100002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction.
    Solomon SD; Skali H; Anavekar NS; Bourgoun M; Barvik S; Ghali JK; Warnica JW; Khrakovskaya M; Arnold JM; Schwartz Y; Velazquez EJ; Califf RM; McMurray JV; Pfeffer MA
    Circulation; 2005 Jun; 111(25):3411-9. PubMed ID: 15967846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vasopeptidase inhibition: a new concept in blood pressure management.
    Burnett JC
    J Hypertens Suppl; 1999 Feb; 17(1):S37-43. PubMed ID: 10340842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vasopeptidase inhibitors in heart failure.
    Dawson A; Struthers AD
    J Renin Angiotensin Aldosterone Syst; 2002 Sep; 3(3):156-9. PubMed ID: 12563565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vasopeptidase inhibition peri- and post-MI in Zucker insulin resistant rats: effect on MI size, arrhythmias, remodeling, function and fetal gene expression.
    Lapointe N; Nguyen QT; Desjardins JF; Tsoporis J; Marcotte F; Pourdjabbar A; Parker TG; Moe G; Adam A; Rouleau JL
    Cardiovasc Drugs Ther; 2005 Oct; 19(5):323-32. PubMed ID: 16382294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemodynamic and humoral effects of vasopeptidase inhibition in canine hypertension.
    Maniu CV; Meyer DM; Redfield MM
    Hypertension; 2002 Oct; 40(4):528-34. PubMed ID: 12364358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effects of omapatrilat and lisinopril on circulating neurohormones and cytokines in patients with chronic heart failure.
    Sheth T; Parker T; Block A; Hall C; Adam A; Pfeffer MA; Stewart DJ; Qian C; Rouleau JL;
    Am J Cardiol; 2002 Sep; 90(5):496-500. PubMed ID: 12208409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual inhibition of angiotensin converting enzyme and neutral endopeptidase produces effective blood pressure control in spontaneously hypertensive rats.
    Kostova E; Jovanoska E; Zafirov D; Jakovski K; Maleska V; Slaninka-Miceska M
    Bratisl Lek Listy; 2005; 106(12):407-11. PubMed ID: 16642666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of vasopeptidase inhibitor omapatrilat on cardiomyocyte apoptosis and ventricular remodeling in rat myocardial infarction.
    Bäcklund T; Palojoki E; Saraste A; Grönholm T; Eriksson A; Lakkisto P; Vuolteenaho O; Nieminen MS; Voipio-Pulkki LM; Laine M; Tikkanen I
    Cardiovasc Res; 2003 Mar; 57(3):727-37. PubMed ID: 12618234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril.
    Trippodo NC; Fox M; Monticello TM; Panchal BC; Asaad MM
    J Cardiovasc Pharmacol; 1999 Dec; 34(6):782-90. PubMed ID: 10598120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omapatrilat--the story of Overture and Octave.
    Coats AJ
    Int J Cardiol; 2002 Nov; 86(1):1-4. PubMed ID: 12243845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the effects of an angiotensin-converting enzyme inhibitor and a vasopeptidase inhibitor after myocardial infarction in the rat.
    Lapointe N; Blais C; Adam A; Parker T; Sirois MG; Gosselin H; Clément R; Rouleau JL
    J Am Coll Cardiol; 2002 May; 39(10):1692-8. PubMed ID: 12020499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct inhibition of neutral endopeptidase in vasopeptidase inhibitor-mediated amelioration of cardiac remodeling in rats with chronic heart failure.
    Maki T; Nasa Y; Tanonaka K; Takahashi M; Takeo S
    Mol Cell Biochem; 2003 Dec; 254(1-2):265-73. PubMed ID: 14674706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.